Biohit Oyj

Helsinki Stock Exchange:BIOBV.HE

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🩺 Medical Instruments

💊 Pharmaceuticals

Location

Finland

Market Cap

USD 47.29 M

Share Price

USD 3.10

Avg Daily Volume

10,720

Change (1 day)

0.34%

Change (1 year)

44.95%

Change (YTD)

30.19%

Biohit Oyj Revenue for the year ending December 31, 2024: USD 14.81 M

Biohit Oyj Revenue is USD 14.81 M for the year ending December 31, 2024, a 2.60% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Biohit Oyj Revenue for the year ending December 31, 2023 was USD 14.43 M, a 23.18% change year over year.
Biohit Oyj Revenue for the year ending December 31, 2022 was USD 11.72 M, a 9.96% change year over year.
Biohit Oyj Revenue for the year ending December 31, 2021 was USD 10.66 M, a 22.47% change year over year.
Biohit Oyj Revenue for the year ending December 31, 2020 was USD 8.70 M, a -22.87% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

Helsinki Stock Exchange: BIOBV.HE

Biohit Oyj

CEO	Prof. Osmo Antero Suovaniemi M.D., Ph.D.
IPO Date	Jan. 3, 2000
Location	Finland
Headquarters	Laippatie 1
Employees	46
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🩺 Medical Instruments 💊 Pharmaceuticals

Description

Biohit Oyj, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. The company's diagnostic tests product range includes the GastroPanel test for diagnosing diseases of the stomach and associated risks; Biohit Active B12, a test for measuring the levels of active vitamin B12; Biohit Total, an indicator of vitamin D status; Biohit Calprotectin, a test for measuring human calprotectin; Helicobacter Pylori Quick Test and Helicobacter Pylori UFT300 Quick Test, a test methods to detect H. pylori infection from a biopsy sample during gastroscopy; ColonView Quick Test, a test for detection of fecal occult blood; Lactose Intolerance Quick Test; Celiac Disease Quick Test; and The GA-map Dysbiosis test, a gut microbiota DNA analysis tool. It also provides monoclonal antibodies for use in cellular pathology, neurobiology, oncology, and human gastric biomarkers research. In addition, the company offers acetaldehyde binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenges, which removes acetaldehyde in smoker's saliva. Further, it provides microplate readers and strip washers, quick test readers, and ThunderBolt, an automated immunoassay analyzer; and products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies, and service laboratory services. The company was founded in 1988 and is headquartered in Helsinki, Finland.